| Primary |
| Hypertension |
13.5% |
| Gastrooesophageal Reflux Disease |
12.2% |
| Product Used For Unknown Indication |
9.5% |
| Pain |
8.1% |
| Gastric Ulcer |
6.1% |
| Cord Blood Transplant Therapy |
5.4% |
| Pyrexia |
5.4% |
| Prophylaxis |
4.7% |
| Abdominal Pain Upper |
4.1% |
| Depression |
3.7% |
| Haemolytic Uraemic Syndrome |
3.4% |
| Lymphoma |
3.4% |
| Antibiotic Therapy |
3.0% |
| Rheumatoid Arthritis |
3.0% |
| Atrial Fibrillation |
2.7% |
| Anxiety |
2.4% |
| Cardiac Failure |
2.4% |
| Chronic Obstructive Pulmonary Disease |
2.4% |
| Cytomegalovirus Infection |
2.4% |
| Gout |
2.4% |
|
| Thrombocytopenia |
14.1% |
| Toxic Skin Eruption |
12.5% |
| Neutropenia |
10.2% |
| Vomiting |
8.6% |
| Hyponatraemia |
6.3% |
| Renal Failure Acute |
5.5% |
| Pancytopenia |
4.7% |
| Transaminases Increased |
4.7% |
| Hepatocellular Injury |
3.9% |
| Malaise |
3.1% |
| Pruritus |
3.1% |
| Rhabdomyolysis |
3.1% |
| Sepsis |
3.1% |
| Tubulointerstitial Nephritis |
3.1% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.3% |
| Hypomagnesaemia |
2.3% |
| Leukopenia |
2.3% |
| Lung Disorder |
2.3% |
| Off Label Use |
2.3% |
| Paraparesis |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
68.9% |
| Gastrooesophageal Reflux Disease |
3.5% |
| Hypertension |
3.2% |
| Drug Use For Unknown Indication |
3.1% |
| Prophylaxis |
2.2% |
| Hiatus Hernia |
1.8% |
| Foetal Exposure During Pregnancy |
1.8% |
| Maternal Exposure Timing Unspecified |
1.8% |
| Gastric Ulcer |
1.7% |
| Pyrexia |
1.5% |
| Pain |
1.4% |
| Barrett's Oesophagus |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Drug Exposure Via Mother |
1.2% |
| Cytomegalovirus Infection |
1.1% |
| Depression |
1.0% |
| Diabetes Mellitus |
0.9% |
| Cough |
0.8% |
| Infection |
0.8% |
| Nausea |
0.7% |
|
| Thrombocytopenia |
15.6% |
| Vomiting |
8.5% |
| Toxic Skin Eruption |
6.6% |
| Hyponatraemia |
6.1% |
| Toxic Epidermal Necrolysis |
5.7% |
| Agranulocytosis |
5.2% |
| Renal Failure Acute |
5.2% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.7% |
| Neutropenia |
4.7% |
| Transaminases Increased |
4.2% |
| Leukopenia |
3.8% |
| Pyrexia |
3.8% |
| Vision Blurred |
3.8% |
| Hepatocellular Injury |
3.3% |
| Hypertriglyceridaemia |
3.3% |
| Pruritus |
3.3% |
| Rash |
3.3% |
| Somnolence |
3.3% |
| Cholestasis |
2.8% |
| Foetal Growth Restriction |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
40.5% |
| Drug Use For Unknown Indication |
10.9% |
| Hypertension |
6.5% |
| Rheumatoid Arthritis |
5.5% |
| Pain |
4.2% |
| Atrial Fibrillation |
3.8% |
| Prophylaxis |
3.1% |
| Hepatitis C |
2.7% |
| Thrombosis Prophylaxis |
2.5% |
| Epilepsy |
2.2% |
| Premedication |
2.2% |
| Anxiety |
2.1% |
| Hiv Infection |
2.0% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Urinary Tract Infection |
1.7% |
| Depression |
1.7% |
| Ankylosing Spondylitis |
1.7% |
| Crohn's Disease |
1.7% |
| Plasma Cell Myeloma |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
|
| Vomiting |
10.6% |
| Renal Failure Acute |
9.2% |
| Thrombocytopenia |
8.9% |
| Renal Failure |
6.8% |
| Pancytopenia |
4.9% |
| Hepatocellular Injury |
4.6% |
| Pulmonary Embolism |
4.3% |
| Pyrexia |
4.3% |
| Septic Shock |
4.3% |
| Weight Decreased |
4.3% |
| Hepatitis |
4.1% |
| Rectal Haemorrhage |
4.1% |
| Somnolence |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Rash |
3.8% |
| Sepsis |
3.8% |
| International Normalised Ratio Increased |
3.5% |
| Rhabdomyolysis |
3.5% |
| Urticaria |
3.5% |
| Tremor |
3.3% |
|
| Interacting |
| Product Used For Unknown Indication |
35.7% |
| Drug Use For Unknown Indication |
10.0% |
| Depression |
8.6% |
| Adrenal Insufficiency |
4.3% |
| Arrhythmia Supraventricular |
4.3% |
| Back Pain |
4.3% |
| Insomnia |
4.3% |
| Secondary Hypothyroidism |
4.3% |
| Extrapyramidal Disorder |
2.9% |
| Gastritis |
2.9% |
| Hypertension |
2.9% |
| Pyrexia |
2.9% |
| Rheumatoid Arthritis |
2.9% |
| Acute Coronary Syndrome |
1.4% |
| Antiinflammatory Therapy |
1.4% |
| Arthralgia |
1.4% |
| Aspergillus Infection |
1.4% |
| Brain Abscess |
1.4% |
| Breast Cancer |
1.4% |
| Coagulopathy |
1.4% |
|
| Renal Failure Acute |
26.3% |
| Drug Interaction |
5.3% |
| Extrapyramidal Disorder |
5.3% |
| General Physical Health Deterioration |
5.3% |
| Hyponatraemia |
5.3% |
| Metastases To Central Nervous System |
5.3% |
| Overdose |
5.3% |
| Prothrombin Time Ratio Decreased |
5.3% |
| Status Epilepticus |
5.3% |
| Suicidal Ideation |
5.3% |
| Tachycardia |
5.3% |
| Thrombosis In Device |
5.3% |
| Toxicity To Various Agents |
5.3% |
| Traumatic Haematoma |
5.3% |
| Weight Decreased |
5.3% |
|
